Why this seasoned money manager sees real upside for this innovative B2B tech startup. on 10/26/2021. Learn More

Sector Expert: Josh Levine

MicroCap Investor

Image: Josh Levine

Josh Levine has 25 years of senior-level experience analyzing trends in bio, energy and information technologies and investing in micro- and small-cap stocks. In 2002 he joined independent investment-research boutique ChangeWave Research, where he became editor of ChangeWave MicroCap Investor in 2004. This became Levine's MicroCap Investor in 2010. He is also senior analyst for ChangeWave Research, which manages a survey network comprised of 25,000 members to track the rate of change in corporate and consumer demand trends and provides the results through an institutional research subscription service. ChangeWave is a service of 451 Research, a leading global analyst and data company focused on the business of enterprise IT innovation.

Recent Interviews

Josh Levine Names Three Biotech Game-Changers (1/3/13)

Micro-cap biotechs must have creative, adaptive management first and foremost, says editor Josh Levine of Josh Levine's MicroCap Investor. A second key characteristic is a technology platform that can ultimately generate a suite of products. In this interview with The Life Sciences Report, Levine shares both his investment philosophy and his best three biotech ideas, all of which he expects will return huge multiples to investors.

Recent Quotes

"It is an opportune time to own or add to your position in CUR."

— Josh Levine, MicroCap Investor (2/6/14)
more >

"CUR aims to complete its phase 2 trial in 18 months; that's momentum, folks."

— Josh Levine, MicroCap Investor (6/20/13)
more >

"OCLS has developed an outstanding medical product called Microcyn."

The Life Sciences Report Interview with Josh Levine (1/3/13)
more >

"CUR has a very compelling technology platform."

The Life Sciences Report Interview with Josh Levine (1/3/13)
more >

Due to permission requirements, not all quotes are shown.